Omalizumab, an anti-immunoglobulin E antibody: state of the art

References

• Bennich HH Ishizaka K Johansson SG Rowe DS Stanworth DF Terry WD Immunoglobulin E: a new class of human immunoglobulin Immunology 1968 15 323 324 4176102
   PubMed Web of Science ®Google Scholar
• Wide L Bennich H Johansson SG Diagnosis of allergy by an in-vitro test for allergen antibodies Lancet 1967 2 1105 1107 4168552
   PubMed Web of Science ®Google Scholar
• Siraganian RP Mechanisms of IgE-mediated hypersensitivity Middleton E Reed CE Ellis EF Adkinson NF Yunginger JW Busse WW Allergy Principles and Practice St Louis, MI Mosby 1993
   Google Scholar
• Kohler G Milstein C Continuous cultures of fused cells secreting antibody of predefined specificity Nature 1975 256 495 497 1172191
   PubMed Web of Science ®Google Scholar
• Jardieu PM Fick RBJ IgE inhibition as a therapy for allergic disease Int Arch Allergy Immunol 1999 118 112 115 10224354
   PubMed Web of Science ®Google Scholar
• Schulman ES Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders Am J Respir Crit Care Med 2001 164 S6 S11 11704611
   PubMed Web of Science ®Google Scholar
• Milgrom H Berger W Najak A Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab) Pediatrics 2001 108 E36 11483846
   PubMed Web of Science ®Google Scholar
• Corren J Casale TB Lanier B Buhl R Holgate S Jimenez P Safety and tolerability of omalizumab Clin Exp Allergy 2009 39 788 797 19302249
   PubMed Web of Science ®Google Scholar
• Hendeles L Sorkness CA Anti-immunoglobulin E therapy with omalizumab for asthma Ann Pharmacother 2007 41 1397 1410 17698897
   PubMed Web of Science ®Google Scholar
• De Bisschop MB Bellou A Anaphylaxis Curr Opin Crit Care 2012 18 308 317 22732436
   PubMed Web of Science ®Google Scholar
• Simons A Real-life effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma at a single UK hospital Am J Respir Crit Care Med 2010 181 A1336
   PubMed Web of Science ®Google Scholar
• Worm M Babina M Hompes S Causes and risk factors for anaphylaxis J Dtsch Dermatol Ges 2013 11 44 50 23181736
   PubMed Web of Science ®Google Scholar
• Mauro M Incorvaia C Formigoni C Elia R Russello M Pellegrino D The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology Panminerva Med 2012 54 305 312 23123583
   PubMed Web of Science ®Google Scholar
• Walker S Monteil M Phelan K Lasserson TJ Walters EH Anti-IgE for chronic asthma in adults and children Cochrane Database Syst Rev 2006 2 CD003559 16625585
   PubMed Web of Science ®Google Scholar
• D’Amato G Perticone M Bucchioni E Salzillo A D’Amato M Liccardi G Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update Eur Ann Allergy Clin Immunol 2010 42 135 140 21114196
   PubMedGoogle Scholar
• Busse WW Morgan WJ Gergen PJ Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children N Engl J Med 2011 364 1005 1015 21410369
   PubMed Web of Science ®Google Scholar
• Brusselle G Michils A Louis R Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Respir Med 2009 103 1633 1642 19619998
   PubMed Web of Science ®Google Scholar
• Cazzola M Camiciottoli G Bonavia M Italian real-life experience of omalizumab Respir Med 2010 104 1410 1416 20483574
   PubMed Web of Science ®Google Scholar
• Barnes N Menzies-Gow A Mansyr AH Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real world study J Asthma 2013 50 529 536 23574000
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L Zureik M Aubier M Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma Chest 2013 143 398 405 23505637
   PubMed Web of Science ®Google Scholar
• Deschildre A Marguet C Salleron J Add-on omalizumab in children with severe allergic asthma: a one year real life survey Eur Respir J 3 21 2013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• Garcia G Magnan A Chiron R A proof of concept randomized controlled trial of omalizumab in patients with severe difficult to control nonatopic asthma Chest 2013 144 411 419 23579324
   PubMed Web of Science ®Google Scholar
• Barnes PJ Intrinsic asthma: not so different from allergic asthma but driven by superantigens? Clin Exp Allergy 2009 39 1145 1151 19538350
   PubMed Web of Science ®Google Scholar
• Marone G Rossi FW Detoraki A Role of superallergens in allergic disorders Chem Immunol Allergy 2007 93 195 213 17369707
   PubMedGoogle Scholar
• Luskova P Draber P Modulation of the Fcepsilon receptor I signaling by tyrosine kinase inhibitors. Search for therapeutic targets of inflammatory and allergy diseases Curr Pharm Des 2004 10 1727 1737 15180535
   PubMed Web of Science ®Google Scholar
• Zaidi AK Saini SS Macglashan DW Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab J Allergy Clin Immunol 2010 125 902 906 20236696
   PubMed Web of Science ®Google Scholar
• Lavaud F Bonniaud P Dalphin JC Usefulness of omalizumab in the patients with severe occupational asthma Allergy 2013 68 813 815 23647648
   PubMed Web of Science ®Google Scholar
• Nopp A Johansson SG Adedoyin J After 6 years with Xolair; a 3-year withdrawal follow-up Allergy 2010 65 56 60 19796193
   PubMed Web of Science ®Google Scholar
• Incorvaia C Masieri S Scurati S Soffia S Puccinelli P Frati F The current role of sublingual immunotherapy in the treatment of allergic rhinitis in adults and children J Asthma Allergy 2011 4 13 17 21660176
   PubMedGoogle Scholar
• Bahadori K Quon BS Doyle-Waters MM Marra C Fitzgerald JM A systematic review of economic evaluations of therapy in asthma J Asthma Allergy 2010 3 33 42 21437038
   PubMedGoogle Scholar
• Campbell JD Spackman DE Sullivan SD The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective Allergy 2010 65 1141 1148 20148804
   PubMed Web of Science ®Google Scholar
• Menzella F Facciolongo N Piro R Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up Ther Adv Respir Dis 2012 6 87 95 22323442
   PubMed Web of Science ®Google Scholar
• van Nooten F Stern S Braunstahl GJ Thompson C Groot M Brown RE Cost-effectiveness of omalizumab for uncontrolled asthma in The Netherlands J Med Econ 2013 16 342 348 23216016
   PubMedGoogle Scholar
• Hoshino M Ohtawa J Effects of adding omalizumab, an anti-immunoglobulin e antibody, on airway wall thickening in asthma Respiration 2012 83 520 528 22236804
   PubMed Web of Science ®Google Scholar
• Riccio AM Dal Negro RW Micheletto C Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infilitration in severe persistent allergic asthma patients Int J Immunopathol Pharmacol 2012 25 475 484 22697079
   PubMed Web of Science ®Google Scholar
• Casale TB Condemi J LaForce C Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial JAMA 2001 286 2956 2967 11743836
   PubMed Web of Science ®Google Scholar
• Chervinsly P Casale T Townley R Omalizumab, and anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis Ann Allergy Asthma Immunol 2003 91 160 167 12952110
   PubMed Web of Science ®Google Scholar
• Humbert M Boulet LP Niven RM Panahloo Z Blogg M Ayre G Omalizumab therapy: patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis Allergy 2009 64 81 84 19076535
   PubMed Web of Science ®Google Scholar
• Verbruggen K Van Cauwenberge P Bachert C Anti-IgE for the treatment of allergic rhinitis – and eventually nasal polyps? Int Arch Allergy Immunol 2009 148 87 98 18799888
   PubMed Web of Science ®Google Scholar
• Penn R Mikula S The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study Am J Rhinol 2007 21 428 432 17882911
   PubMedGoogle Scholar
• Bains SN Judson MA Allergic bronchopulmonary aspergillosis Clin Chest Med 2012 33 265 281 22640845
   PubMed Web of Science ®Google Scholar
• ven der Ent CK Hoekstra H Rijkers GT Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody Thorax 2007 62 276 277 17329558
   PubMed Web of Science ®Google Scholar
• Kanu A Patel K Treatment of allergic bronchopulmonary aspergillosis (ABPA) with anti-IgE antibody (omalizumab) Pediatr Pulmonol 2008 43 1249 1251 19009619
   PubMed Web of Science ®Google Scholar
• Lebecque P Leonard A Argaz M Godding V Pilette C Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis BMJ Case Rep 2009 2009 pii: bcr07.2008.0379
   Google Scholar
• Lebecque P Leonard A Piletre C Omalizumab for treatment of ABPA exacerbations in CF patients Pediatr Pulmonol 2009 44 516 19382216
   PubMed Web of Science ®Google Scholar
• Collins J Devos G Hudes G Rosenstreich D Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab J Asthma Allergy 2012 5 65 70 23204847
   PubMedGoogle Scholar
• Wong R Wong M Robinson PD Fitzgerald DA Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis Paediatr Respir Rev 2013 14 22 24 23287795
   PubMed Web of Science ®Google Scholar
• Incorvaia C Mauro M Riario-Sforza GG Frati F Tarantini F Caserini M Current and future applications of the anti-IgE antibody omalizumab Biologics 2008 2 67 73 19707429
   PubMedGoogle Scholar
• Sheinkopf LE Rafi AW Do LT Katz RM Klaustermeyer WB Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study Allergy Asthma Proc 2008 29 530 537 18926061
   PubMed Web of Science ®Google Scholar
• Heil PM Maurer D Klein B Hultsch T Stingl G Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course – randomized, placebo-controlled and double-blind pilot study J Dtsch Dermatol Ges 2010 8 990 998 20678148
   PubMed Web of Science ®Google Scholar
• Boyce JA Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE J Allergy Clin Immunol 2006 117 1415 1418 16751006
   PubMed Web of Science ®Google Scholar
• Bullerkotte U Wieczorek D Kapp A Wedi B Effective treatment of refractory severe heat urticaria with omalizumab Allergy 2010 65 931 932 19930230
   PubMed Web of Science ®Google Scholar
• Bindslev-Jensen C Skov PS Efficacy of omalizumab in delayed pressure urticaria: a case report Allergy 2010 65 138 139 19804440
   PubMed Web of Science ®Google Scholar
• Güzelbey O Ardelean E Magerl M Zuberbier T Maurer M Metz M Successful treatment of solar urticaria with anti-immunoglobulin E therapy Allergy 2008 63 1563 1565 18925897
   PubMed Web of Science ®Google Scholar
• Metz M Bergmann P Zuberbier T Maurer M Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy Allergy 2008 63 247 249 18186820
   PubMed Web of Science ®Google Scholar
• Waibel KH Reese DA Hamilton RG Devillez RL Partial improvement of solar urticaria after omalizumab J Allergy Clin Immunol 2010 125 490 491 20159260
   PubMed Web of Science ®Google Scholar
• Sabroe RA Failure of omalizumab in cholinergic urticaria Clin Exp Dermatol 2010 35 127 129
   PubMed Web of Science ®Google Scholar
• Sands MF Blume JW Schwartz SA Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab J Allergy Clin Immunol 2007 120 979 981 17931567
   PubMed Web of Science ®Google Scholar
• Spector SL Tan RA Effect of omalizumab on patients with chronic urticaria Ann Allergy Asthma Immunol 2007 99 190 193 17718108
   PubMed Web of Science ®Google Scholar
• Kaplan AP Joseph K Maykut RJ Geba GP Zeldin RK Treatment of chronic autoimmune urticaria with omalizumab J Allergy Clin Immunol 2008 122 569 573 18774392
   PubMed Web of Science ®Google Scholar
• Maurer M Rosen K Hsieh HJ Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria N Engl J Med 2013 368 924 935 23432142
   PubMed Web of Science ®Google Scholar
• Siebenhaar F Kühn W Zuberbier T Maurer M Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy J Allergy Clin Immunol 2007 120 213 215 17544095
   PubMed Web of Science ®Google Scholar
• Carter MC Robyn JA Bressler PB Walker JC Shapiro GG Metcalfe DD Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis J Allergy Clin Immunol 2007 119 1550 1551 17481708
   PubMed Web of Science ®Google Scholar
• Rueff F Dugas-Breit S Przybilla B Stinging Hymenoptera and mastocytosis Curr Opin Allergy Clin Immunol 2009 9 338 342 19474708
   PubMed Web of Science ®Google Scholar
• Kontou-Fili K Fili CI Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis Allergy 2009 64 1384 1385 19432937
   PubMed Web of Science ®Google Scholar
• Douglass JA Carroll K Voskamp A Bourke P Wei A O’Hehir RE Omalizumab is effective in treating systemic mastocytosis in a non atopic patient Allergy 2010 65 926 927 19889117
   PubMed Web of Science ®Google Scholar
• Bock SA Munoz-Furlong A Sampson HA Fatalities due to anaphylactic reactions to foods J Allergy Clin Immunol 2001 107 191 193 11150011
   PubMed Web of Science ®Google Scholar
• Leung DY Sampson HA Yunginger JW Effects of anti-IgE therapy in patients with peanut allergy N Engl J Med 2003 348 975 976 12637606
   PubMed Web of Science ®Google Scholar
• Jones JD Marney SRJr Fahrenholz JM Idiopathic anaphylaxis successfully treated with omalizumab Ann Allergy Asthma Immunol 2008 101 550 551 19055211
   PubMed Web of Science ®Google Scholar
• Warrier P Casale TB Omalizumab in idiopathic anaphylaxis Ann Allergy Asthma Immunol 2009 102 257 258 19354075
   PubMed Web of Science ®Google Scholar
• Bray SM Fajt ML Petrov AA Successful treatment of exercise-induced anaphylaxis with omalizumab Ann Allergy Asthma Immunol 2012 109 281 282 23010237
   PubMed Web of Science ®Google Scholar
• Robson-Ansley P Toit GD Pathophysiology, diagnosis and management of exercise-induced anaphylaxis Curr Opin Allergy Clin Immunol 2010 10 312 317 20543674
   PubMed Web of Science ®Google Scholar
• Rafi A Do LT Katz R Sheinkopf LE Simons CW Klaustermeyer W Effects of omalizumab in patients with food allergy Allergy Asthma Proc 2010 31 76 83 20167148
   PubMed Web of Science ®Google Scholar
• Savage JH Courneya JP Sterba PM Macglashan DW Saini SS Wood RA Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy J Allergy Clin Immunol 2012 130 1123 1129 22800401
   PubMed Web of Science ®Google Scholar
• Foroughi S Foster B Kim N Anti-IgE treatment of eosinophil-associated gastrointestinal disorders J Allergy Clin Immunol 2007 120 594 601 17765756
   PubMed Web of Science ®Google Scholar
• Foster B Foroughi S Yin Y Prussin C Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders Clin Mol Allergy 2011 9 7 21527026
   PubMedGoogle Scholar
• Ridolo E Montagni M Olivieri E Rogkakou A De’ Angelis GL Canonica GW Eosinophilic esophagitis: which role for food and inhalant allergens? Asia Pac Allergy 2012 2 237 241 23130328
   PubMedGoogle Scholar
• Rocha R Vitor AB Trindade E Omalizumab in the treatment of eosinophilic esophagitis and food allergy Eur J Pediatr 2011 170 1471 1474 21809010
   PubMed Web of Science ®Google Scholar
• Cabanes N Igea JM de la Hoz B Latex allergy: position paper J Investig Allergol Clin Immunol 2012 22 313 330
   PubMed Web of Science ®Google Scholar
• Leynadier F Doudou O Gaouar H Effect of omalizumab in health care workers with occupational latex allergy J Allergy Clin Immunol 2004 113 360 361 14767458
   PubMed Web of Science ®Google Scholar
• Calonge M Herreras JM Clinical grading of atopic keratoconjunctivitis Curr Opin Allergy Clin Immunol 2007 7 442 445 17873586
   PubMed Web of Science ®Google Scholar
• Williams PB Sheppard JDJr Omalizumab: a future innovation for treatment of severe ocular allergy? Exp Opin Biol Ther 2005 5 1603 1609
   PubMed Web of Science ®Google Scholar
• Taillé C Doan S Neukirch C Aubier M Omalizumab for severe atopic keratoconjunctivitis BMJ Case Rep 2010 2010 pii: bcr0420102919
   Google Scholar
• Bard S Paravisini A Avilés-Izquierdo JA Fernandez-Cruz E Sánchez-Ramón S Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab Arch Dermatol 2008 144 1662 1663 19075161
   PubMed Web of Science ®Google Scholar
• Lee J Doggweiler-Wiygul R Kim S Hill BD Yoo TJ Is interstitial cystitis an allergic disorder? A case of interstitial cystitis treated successfully with anti-IgE Int J Urol 2006 13 631 634 16771742
   PubMed Web of Science ®Google Scholar
• Fairley JA Baum CL Brandt DS Messingham KA Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab J Allergy Clin Immunol 2009 123 704 705 19152970
   PubMed Web of Science ®Google Scholar
• Pinto JM Mehta N DiTineo M Wang J Baroody FM Naclerio RM A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis Rhinology 2010 48 318 324 21038023
   PubMed Web of Science ®Google Scholar
• Bobolea I Barranco P Fiandor A Cabañas R Quirce S Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease J Investig Allergol Clin Immunol 2010 20 448 449
   PubMed Web of Science ®Google Scholar
• Parks KW Casale TB Anti-immunoglobulin E monoclonal antibody administered with immunotherapy Allergy Asthma Proc 2006 27 Suppl 1 S33 S36 16722330
   PubMed Web of Science ®Google Scholar
• Incorvaia C Frati F Puccinelli P Riario-Sforza GG Dal Bo S Dose dependence of efficacy and safety of subcutaneous immunotherapy Monaldi Arch Chest Dis 2006 65 41 43 16700193
   PubMedGoogle Scholar
• Massanari M Nelson H Casale T Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma J Allergy Clin Immunol 2010 125 383 389 20159249
   PubMed Web of Science ®Google Scholar
• Kamin W Kopp MV Erdnuess F Schauer U Zielen S Wahn U Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously Pediatr Allergy Immunol 2010 21 160 165
   PubMed Web of Science ®Google Scholar
• Kopp MV Hamelmann E Zielen S Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma Clin Exp Allergy 2009 39 271 279 19016798
   PubMed Web of Science ®Google Scholar
• Müller UR Helbling A Berchtold E Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety J Allergy Clin Immunol 1992 89 529 534 1740583
   PubMed Web of Science ®Google Scholar
• Schulze J Rose M Zielen S Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab Allergy 2007 62 963 964 17484729
   PubMed Web of Science ®Google Scholar
• Rerinck HC Rueff F Przybilla B Recurrent severe anaphylactic reactions to venom immunotherapy (VIT): omalizumab induces tolerance J Allergy Clin Immunol 2008 Suppl 29 111
   Google Scholar
• Galera C Soohun N Zankar N Caimmi S Gallen C Demoly P Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab J Investig Allergol Clin Immunol 2009 19 225 229
   PubMed Web of Science ®Google Scholar
• Soriano Gomis V Gonzalez Delgado P Niveiro Hernandez E Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy J Investig Allergol Clin Immunol 2008 18 225 226
   PubMed Web of Science ®Google Scholar
• Kopp MV Omalizumab: and anti-IgE therapy in allergy Curr Allergy Asthma Rep 2011 11 101 116 21243454
   PubMed Web of Science ®Google Scholar
• Sanchez J Ramirez R Diez S Omalizumab beyond asthma Allergol Immunopathol (Madr) 2012 40 306 315 22264640
   PubMed Web of Science ®Google Scholar
• Babu KS Polosa R Morjaria JB Anti-IgE – emerging opportunities for omalizumab Expert Opin Biol Ther 2013 13 765 777 23517576
   PubMed Web of Science ®Google Scholar
• Shankar T Petrov AA Omalizumab and hypersensitivity reactions Curr Opin Allergy Clin Immunol 2013 13 19 24 23242113
   PubMed Web of Science ®Google Scholar